

curriculum vitae

Fabrizio Stocchi

Marana di Montereale (AQ) 22/09/1958



CURRICULUM VITAE

| Contact Details | | | |
|--------------------------|--|----------------------|-----------------------------|
| Full Name | prof. Fabrizio Stocchi | | |
| JobTitle/Position | Full Professor of Neurology. Settore: MED/26 NEUROLOGIA Settore concorsuale: 06/D6 Università Telematica San Raffaele Roma Director of the research centre for Parkinson's disease and Movement | | |
| Institution Name | Department of Neurology – Clinical Trial Centre – IRCCS San Raffaele Pisana | | |
| Work Address | IRCCS San Raffaele Pisana Via della Pisana 235 00163, Rome, Italy | | |
| Telephone | +39.06.52252311 | Fax Number | +39.06. 66058486 |
| Mail | fabrizio.stocchi@sanraffaele.it fabrizio.stocchi@fastwebnet.it | | |
| Education Details | | | |
| Institution Name | University of l'Aquila, Faculty of Medicine | | |
| Date | 28 th July, 1983 | Qualification | Medicine and Surgery Degree |
| Institution Name | University of Rome "La Sapienza" | | |
| Date | 24 th July, 1987 | Qualification | Specialization in Neurology |
| Institution Name | University of Catania | | |

| | | | |
|--|--|----------------------|----------------------|
| Date | 1989-1992 | Qualification | Ph.D in Neurobiology |
| Experience Details | | | |
| Institution Name | University of l' Aquila | | |
| Job | | Date | 1979-1983 |
| Brief Description | Clinical Internship and academic appointments | | |
| Institution Name | King's College Hospital - London | | |
| Job | Research S.H.O., Dept. of | Date | 1984-1985 |
| Brief Description | Clinical Internship and academic appointments | | |
| Institution Name | Dept. of Neurological Sciences, University of Rome | | |
| Job title/Position | Research fellow | Date | 1985-1986 |
| Brief Description | Clinical Internship and academic appointments | | |
| Institution Name | King's College Hospital - London | | |
| JobTitle/Position | Research S.H.O., Dept. of | Date | 1986-1987 |
| Brief Description | Clinical Internship and academic appointments | | |
| Institution Name | Dept. of Neuroscience, University of Rome "La Sapienza" | | |
| JobTitle/Position | Neurologist | Date | 1987-1990 |
| Brief Description | Clinical Internship and academic appointments | | |
| Institution Name | National Hospital for Neurology and Neurosurgery, London | | |
| JobTitle/Position | Research Registrar | Date | 1990-1992 |
| Brief Description | Clinical Internship and academic | | |
| Institution Name | Dept. of Neuroscience, University of Rome | | |
| JobTitle/Position | Research Registrar | Date | 1992-1993 |
| Brief Description | Clinical Internship and academic | | |
| Institution Name | IRCCS "Neuromed" Pozzilli, (IS) | | |
| JobTitle/Position | Research supervisor | Date | 1995-2005 |
| Brief Description | Clinical Internship and academic | | |
| Institution Name | IRCCS "San Raffaele" Pisana (RM) | | |
| JobTitle/Position | Director of Clinical Trial Center and Movement Disorder Center | Date | 2006 - ongoing |
| Brief Description | Clinical Internship and academic | | |
| JobTitle/Position | Professor of Neurology | Date | 2015 - ongoing |
| Brief Description | University Telematica San Raffaele | | |
| Publication Details | | | |
| Principal Investigator in more than 60 Clinical Trial in the past 10 years | | | |
| Official H index: 51.0 | | | |
| Source: Scopus - Scopus Author Id: 7005546848 | | | |
| ORCID ID: 0000-0002-5763-0033 - RESEARCH ID: K-5089-2016 | | | |
| Other Details: Awards and Honors | | | |



Scientific cooperation agreement and Exanche of researchers between "National Research Council (CNR)" and "British Council" from 08/1986 to 11/1986
Referee activity for the Editorial Board of several international journals
Romanian Academy of Medical Sciences - Member of Honour, from 10/2002
The Movement Disorder Society - Member of the Scientific Issues Committee, from 01/2003 to 12/2004
The Movement Disorder Society - Member of the Archives Committee, form 01/2012
Co-Chairman conference of THE PONTIFICAL ACADEMY OF SCIENCES 5-6 Aprile 2011

GCP Training completed (last on Jan/2016)

| | |
|--------------------------------|----------------|
| Medical Licence No. | AQ 1745 |
|--------------------------------|----------------|

Io sottoscritto autorizzo al trattamento dei dati personali
secondo la DLGs 196/2003

01/01/2017


Centro per lo studio e la cura Del Morbo di Parkinson
e disturbi del movimento
Direttore Prof. Fabrizio Stocchi

Publications:

1. Adjuvant therapies for Parkinson's disease: Critical evaluation of safinamide. Stocchi F, Torti M. *Drug Design, Development and Therapy*. 10: 609-618; 2016
2. Long-term effects of rasagiline and the natural history of treated Parkinson's disease. Rascol O, Hauser RA, Stocchi F, Fitzer-Attas CJ, Sidi Y, Abler V, Olanow CW; AFU Investigators. *Mov Disord*. 31(10):1489-1496; 2016.
3. Advances in dopamine receptor agonists for the treatment of Parkinson's disease. Stocchi F, Torti M, Fossati C. *Expert Opin Pharmacother. Expert Opin Pharmacother*. 17(14): 1889-902; 2016.
4. Robot-assisted gait training versus treadmill training in patients with Parkinson's disease: a kinematic evaluation with gait profile score. Galli M, Cimolin V, De Pandis MF, Le Pera D, Sova I, Albertini G, Stocchi F, Franceschini M. *Funct Neurol*. 2016 Jul 18:1-8.
5. Mavoglurant in Parkinson's Patients With I-Dopa-Induced Dyskinesias: Two Randomized Phase 2 Studies. Trenkwalder C, Stocchi F, Poewe W, Dronamraju N, Kenney C, Shah A, von Raison F, Graf A. *Mov Disord*. 2016 Jul;31(7):1054-8; 2016.

6. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease. LeWitt PA, Hauser RA, Grosset DG, Stocchi F, Saint-Hilaire MH, Ellenbogen A, Leinonen M, Hampson NB, DeFeo-Fraulini T, Freed MI, Kieburtz KD. *Mov Disord.* 31(9):1356-65; 2016
7. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B. *Mov Disord.* Jul;31(7):1049-54; 2016
8. Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide. Stocchi F, Torti M. *Drug Des Devel Ther.* 5; 10: 609-18; 2016.
9. Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned. Hauser RA, Stocchi F, Rascol O, Huyck SB, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt D. *JAMA Neurol.* 1;72(12):1491-1500; 2015
10. The Parkinsonian Gait Spatiotemporal Parameters Quantified by a Single Inertial Sensor before and after Automated Mechanical Peripheral Stimulation Treatment. Kleiner A, Galli M, Gaglione M, Hildebrand D, Sale P, Albertini G, Stocchi F, De Pandis MF. *Parkinsons Dis.* 2015:39051; 2015
11. Acute Modulation of Brain Connectivity in Parkinson Disease after Automatic Mechanical Peripheral Stimulation: A Pilot Study. Quattrocchi CC, De Pandis MF, Piervincenzi C, Galli M, Melgari JM, Salomone G, Sale P, Mallio CA, Carducci F, Stocchi F. *PLoS One.* Oct 15;10(10):e0137977; 2015
12. Rasagiline for the treatment of Parkinson's disease: an update. Stocchi F, Fossati C, Torti M. *Expert Opin Pharmacother.* 16(14): 2231-41; 2015
13. L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised Study. Stocchi F, Vacca L, Grassini P, Pawsey S, Whale H, Marconi S, Torti M. *Parkinsons Dis.* doi: 10.1155/2015/369465; 2015
14. Long-term effects of automated mechanical peripheral stimulation on gait patterns of patients with Parkinson's disease. Stocchi F, Sale P, Kleiner AF, Casali M, Cimolin V, de Pandis F, Albertini G, Galli M. *Int J Rehabil Res.* 38(3): 238-45; 2015
15. The Lee Silverman Voice Treatment (LSVT®) speech therapy in progressive supranuclear palsy. Sale P, Castiglioni D, De Pandis MF, Torti M, Dall'Armi V, Radicati FG, Stocchi F. *Eur J Phys Rehabil Med.* 51(5): 569-74; 2015
16. Neuroprotection in Parkinson's disease: a difficult challenge. Stocchi F. *Lancet Neurol.* 14(8); 780-1; 2015



17. Prevalence and associated features of self-reported freezing of gait in Parkinson disease: The DEEP FOG study. Amboni M, Stocchi F, Abbruzzese G, Morgante L, Onofri M, Ruggieri S, Tinazzi M, Zappia M, Attar M, Colombo D, Simoni L, Ori A, Barone P, Antonini A; DEEP Study Group. *Parkinsonism Relat Disord.* 21(6): 644-649; 2015
18. Timed Up and Go test and wearable inertial sensor: a new combining tool to assess change in subject with Parkinson's disease after automated mechanical peripheral stimulation treatment. Galli M, Kleinera A, Gaglione M, Sale P, Alberini G, Stocchi F, De Pandis MF. *International Journal of Engineering and Innovative Technology (IJEIT)*, 4(11): 155-163; 2015
19. The "Gender Factor" in Wearing-Off among Patients with Parkinson's Disease: A Post Hoc Analysis of DEEP Study. Colombo D, Abbruzzese G, Antonini A, Barone P, Bellia G, Franconi F, Simoni L, Attar M, Zagni E, Haggiag S, Stocchi F. *ScientificWorldJournal.* 787451; 2015
20. How to optimize the treatment of early stage Parkinson's disease. Stocchi F, Vacca L, Radicati FG. *Translational Neurodegeneration* 4:4 doi:10.1186/2047-9158-4-4; 2015
21. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. Smith KM, Eyal E, Weintraub D; ADAGIO Investigators. (Bueri J, Garretto N, Mejia R, Gershanik O, Giannula R, Micheli F, Wolf E, Guttman M, Hobson D, Hobson DE, Jog M, King D, Mendis T, Miyasaki J, Panisset M, Pourcher E, Rajput A, Ranawaya R, Tsui J, Cesaro P, Damier P, Destee A, Durif F, Slaoui T, Tison F, Viallet F, Deuschl G, Gasser T, Ludolph A, Oehlwein C, Przuntek H, Reifschneider G, Schnitzler A, Trenkwalder C, Bokor M, Katona A, Lajtos J, Nikl J, Takats A, Valikovics A, Badarny S, Djaldetti R, Giladi N, Hassin S, Rabey JM, Reches A, Schwartz M, Wirguin I, Albanese A, Bentivoglio A, Bonuccelli U, Calzetti S, Comi G, Curatola L, Ferrarese C, Lamberti P, Marconi R, Martignoni E, Maugeri S, Mecocci G, Ruggieri S, Stocchi F, Bomhof MA, Krul JM, Leenders KL, Cunha L, Ferreira J, Bajenaru OA, Carciumaru N, Bulboaca AC, Pascu I, Simu M, Calopa M, García JM, Kulisevsky J, Linzasoro C, Gipúzkoa P, Miquel F, Posada IJ, Martí MJ, Burn D, MacMahon D, Barker R, Allen N, Barbour P, Bertoni J, Bharucha K, Bose S, Drasby E, Elble R, Elmer L, Evans B, Fernandez H, Friedman J, Hull K, Golbe L, Goudreau J, Guttuso T, Hassan M, Hauser R, Hermanowicz N, Houser M, Hurtig H, Isaacson S, Jennings D, Kompolti A, Morgan J, Murphy J, Nausieda P, Pahwa R, Parashos S, O'Suilleabhain P, Racette B, Reich S, Roberts J, Rothstein T, Sahay A, Saint-Hilaire M, Schiess M, Scott B, Shahed J, Simuni T, Smith R, Struck L, Sutton J, Swope D, Tagliati M, Tetrad J, Togasaki D, Watts R). *JAMA Neurol.* 72(1):88-95; 2015
22. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Poewe W, Seppi K, Fitzer-Attas CJ, Wenning GK, Gilman S, Low PA, Giladi N, Barone P, Sampaio C, Eyal E, Rascol O; Rasagiline-for-MSA investigators. (Chelimsky T, Colcher A, Hermanowicz PD, Jankovic J, Liang G, Marshall F, Novak P, Pagan F, Criswell S, Hauser R, Robertson D, Lessig S, Isaacson S, Panisset M, Mendis T, Pourcher E, Cloutier M, Colosimo C, Albanese A, Orefice G, Stocchi F, Antonini A, Cortelli P, Tolosa E, Kulisevsky J, Mir P, Oertel W, Ludolph A, Deuschl G, Berg D, Lorenzl S,



Reichmann H, Schmidt R, Mathias C, Burn D, Morris H, Meissner W, Destee A, Coelho M, Hovestadt A, Van Domburg P, Takats A, Lajtos J, Valikovics A, Djaldetti R, Hassin S, Gurevich T, Shlesinger I.) *Lancet Neurol.* 14(2):145-52; 2015

23. The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: A simple grading system. Chaudhuri KR, Sauerbier A, Rojo JM, Sethi K, Schapira AH, Brown RG, Antonini A, Stocchi F, Odin P, Bhattacharya K, Tsuboi Y, Abe K, Rizos A, Rodriguez-Blazquez C, Martinez-Martin P. *Parkinsonism Relat Disord.* 21(3):287-91; 2015
24. Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy. Italiano D, Bianchini E, Ilardi M, Cilia R, Pezzoli G, Zanettini R, Vacca L, Stocchi F, Bramanti P, Ciurleo R, Di Lorenzo G, Polimeni G, de Luise C, Ross D, Rijnbeek P, Sturkenboom M, Trifirò G. *J Neural Transm.*122(6):799-808; 2015
25. Move for Change Part III: a European survey evaluating the impact of the EPDA Charter for People with Parkinson's Disease. Bloem BR, Stocchi F. *Eur J Neurol.* 22(1):133-41; 2015
26. Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: An international multicenter study. Rizos A, Martinez-Martin P, Odin P, Antonini A, Kessel B, Kozul TK, Todorova A, Douiri A, Martin A, Stocchi F, Dietrichs E, Chaudhuri KR; EUOPAR and the IPDMDS non-Motor PD Study Group. *Parkinsonism Relat Disord.* 20(11):1231-5; 2014
27. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Stocchi F, Hsu A, Khanna S, Ellenbogen A, Mahler A, Liang G, Dillmann U, Rubens R, Kell S, Gupta S. *Parkinsonism Relat Disord.* 20; 1335-40; 2014
28. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R; the Study 018 Investigators¹¹. *Mov Disord.* 29(10):1273-80; 2014
29. The relevance of dopaminergic level in nocturnal disability in Parkinson's disease: implications of continuous dopaminergic stimulation at night to treat the symptoms. Stocchi F, Stirpe P. *J Neural Transm.* 121 Suppl 1:79-83; 2014
30. Prevalence of fatigue in Parkinson disease and its clinical correlates. Stocchi F, Abbruzzese G, Ceravolo R, Cortelli P, D'Amelio M, De Pandis MF, Fabbrini G, Pacchetti C, Pezzoli G, Tessitore A, Canesi M, Iannacone C, Zappia M; For the FORTE Study Group. *Neurology.* 15; 83(3): 215-20; 2014
31. A Systems Medicine Clinical Platform for Understanding and Managing Non-Communicable Diseases. Cesario A, Auffray C, Agusti A, Apolone G, Balling R, Barbanti P, Bellia A, Boccia S, Bousquet J, Cardaci V, Cazzola M, Dall'Armi V, Daraselia N, Ros LD, Bufalo AD, Ducci G, Ferri L, Fini M, Fossati C, Gensini G, Granone PM, Kinross J, Lauro D, Cascio GL, Lococo F, Lococo A, Maier D, Marcus F, Margaritora S, Marra C, Minati G, Neri M, Pasqua F, Pison C, Pristipino C, Roca J, Rosano G, Rossini PM, Russo P, Salinaro G, Shenhar S, Soreq H, Sterk PJ,



- Stocchi F, Torti M, Volterrani M, Wouters EF, Frustaci A, Bonassi S. *Curr Pharm Des.* 20(38): 5945-56; 2014
32. Effects of robot assisted gait training in progressive supranuclear palsy (PSP): a preliminary report. Sale P, Stocchi F, Galafate D, De Pandis MF, Le Pera D, Sova I, Galli M, Foti C, Franceschini M. *Front Hum Neurosci.* 17; 8:207; 2014
33. Drug safety evaluation of ropinirole prolonged release. Stocchi F, Radicati FG, Torti M. *Expert Opin Drug Saf.* 13(3): 383-9; 2014
34. Initiating levodopa therapy for Parkinson's disease. Olanow C, Kieburtz K, Stocchi F. *Mov Disord.* 29 Suppl 3:430; 2014
35. Therapy for Parkinson's Disease: What is in the Pipeline? Stocchi F. *Neurotherapeutics.* 11(1): 24-33; 2014
36. Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's disease. Stocchi F; The ADAGIO investigators. *Eur J Neurol.* 21(2): 357-60; 2014
37. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R; for the Study 016 Investigators. *Mov Disord.* 29(2): 229-37; 2014
38. Early DEtection of wEaring off in Parkinson disease: The DEEP study. Stocchi F, Antonini A, Barone P, Tinazzi M, Zappia M, Onofrj M, Ruggieri S, Morgante L, Bonuccelli U, Lopiano L, Pramstaller P, Albanese A, Attar M, Posocco V, Colombo D, Abbruzzese G; DEEP study group. *Parkinsonism Relat Disord.* 20(2): 204-11; 2014
39. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C. *Mov Disord.* 28(13): 1838-46; 2013
40. Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism. Quadri M, Fang M, Picillo M, Olgiati S, Breedveld GJ, Graafland J, Wu B, Xu F, Erro R, Amboni M, Pappatà S, Quarantelli M, Annesi G, Quattrone A, Chien HF, Barbosa ER; International Parkinsonism Genetics Network, Oostra BA, Barone P, Wang J, Bonifati V. Collaborators: Bonifati V, Maat-Kievit A, Rood J, Boon A, van de Warrenburg B, Delnooz C, Rietveld A, Bloem B, Ferreira J, Correia Guedes L, Tolosa E, Janssens S, Emre M, Hanagasi H, Bilgic B, Elibol B, Socal M, Jardim L, Chien HF, Barbosa ER, Lu CS, Wu-Chou YH, Yeh TH, Atadzhanov M, Kelly P, Lopiano L, Tassorelli C, Pacchetti C, Nappi G, Riboldazzi G, Bono G, Padovani A, Borroni B, Raudino F, Di Fonzo A, Volonte A, Fincati E, Bertolasi L, Tinazzi M, Bonizzato A, Ferracci C, Dalla Libera A, Cortelli P, Capellari S, Marini P, Massaro F, Federico A, Taglia I, Battisti C, Marconi R, Onofrj M, Thomas A, Vanacore N, Meco G, Fabbrini G, Fabrizio E, Manfredi M, Berardelli A, Stocchi F, Vacca L, De Michele G, Criscuolo C, Santoro L, Filla A, De Mari M, Dell C, Iliceto G,



- Lamberti P, Toni V, Trianni G, Gagliardi M, Annesi G, Quattrone A, Saddi V, Francesco S, Saddi V, Cossu G, Melis M. *Hum Mutat.* 34(9): 1208-15; 2013
41. Robot-assisted walking training for individuals with Parkinson's disease: a pilot randomized controlled trial. Sale P, De Pandis MF, Stocchi F, Domenica LP, Sova I, Cimolin V, Ancillao A, Albertini G, Galli M, Franceschini M. *BMC Neurol.* 24;13(1): 50; 2013
 42. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F; Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) Investigators. *Mov Disord.* 28(8): 1064-71; 2013
 43. A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. Ray Chaudhuri K, Rojo JM, Schapira AH, Brooks DJ, Stocchi F, Odin P, Antonini A, Brown RJ, Martinez-Martin P. *PLoS One.* 8(2):e57221; 2013
 44. Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies. Onofrj M, Varanese S, Bonanni L, Taylor JP, Antonini A, Valente EM, Petrucci S, Stocchi F, Thomas A, Perfetti B. *J Neurol.* 260(7): 1731-42; 2013
 45. Obstacles to the development of a neuroprotective therapy for Parkinson's disease. Stocchi F, Olanow CW. *Mov Disord.* 28(1): 3-7; 2013
 46. The vatican meeting on neuroprotection for Parkinson's disease. Olanow CW, Obeso JA, Stocchi F. *Mov Disord.* 28(1):1-2; 2013
 47. Move for Change Part II: a European survey evaluating the impact of the EPDA Charter for people with Parkinson's disease. Stocchi F, Bloem BR. *Eur J Neurol.* 20(3): 461-472; 2013
 48. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. Schapira AH, Stocchi F, Borgohain R, Onofrj M, Bhatt M, Lorenzana P, Lucini V, Giuliani R, Anand R. *Eur J Neurol.* 20(2): 271-280; 2013
 49. The relation between Parkinson's disease and ageing - Comparison of the gait patterns of young Parkinson's disease subjects with healthy elderly subjects. Sale P, De Pandis MF, Vimercati SL, Sova I, Foti C, Tenore N, Fini M, Stocchi F, Albertini G, Franceschini M, Galli M. *Eur J Phys Rehabil Med.* 49(2): 161-167; 2013
 50. A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease. Bonuccelli U, Meco G, Fabbrini G, Tessitore A, Pierantozzi M, Stocchi F, Ceravolo R, Caltagirone C, Silvestrini M, Morgante F, Ruggieri S, Avanzino L, Guadagna M, Dell'Agnello G, Rossi A, Spezia R, Mancini M. *Expert Opin Pharmacother.* 13(16): 2269-80; 2012
 51. Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinson's disease. Abbruzzese G, Antonini A, Barone P, Stocchi F, Tamburini T,



- Bernardi L, Amboni M, Vacca L, Posocco V, Colombo D. *Neurol Sci.* 33(6):1319-27; 2012
52. Observational study of sleep-related disorders in Italian patients with Parkinson's disease: usefulness of the Italian version of Parkinson's disease sleep scale. Pellecchia MT, Antonini A, Bonuccelli U, Fabbrini G, Ferini Strambi L, Stocchi F, Battaglia A, Barone P. *Neurol Sci.* 33(3): 689-94; 2012
53. Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. Marconi R, Antonini A, Barone P, Colosimo C, Avarello TP, Bottacchi E, Cannas A, Ceravolo MG, Ceravolo R, Cicarelli G, Gaglio RM, Giglia L, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatralè R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Del Dotto P, De Gaspari D, Grasso L, Morgante F, Santangelo G, Fabbrini G, Morgante L. *Neurol Sci.* 33(3):585-93; 2012
54. Move for Change Part I: a European survey evaluating the impact of the EPDA Charter for People with Parkinson's disease. Bloem BR, Stocchi F. *Eur J Neurol.* 19 (3): 402-10; 2012
55. The possible clinical predictors of fatigue in Parkinson's disease: a study of 135 patients as part of international nonmotor scale validation project. Metta V, Logishetty K, Martinez-Martin P, Gage HM, Schartau PE, Kaluarachchi TK, Martin A, Odin P, Barone P, Stocchi F, Antonini A, Chaudhuri KR. *Parkinsons Dis. SAGE-Hindawi Access to Research; Parkinson's Disease Volume 2011, Article ID 125271, 7 pages; 2011*
56. Temporal stability of the Unified Dyskinesia Rating Scale. Goetz CG, Stebbins GT, Theeuwes A, Stocchi F, Ferreira JJ, van de Witte S, Bronzova J. *Mov Disord.* 26 (14): 2556-9; 2011
57. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Stocchi F, Borgohain R, Onofri M, Schapira AH, Bhatt M, Lucini V, Giuliani R, Anand R; for the Study 015 Investigators. *Mov Disord.* 27; 106-112; 2012
58. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease. Stocchi F, Rabey JM. *Eur J Neurol.* 18 (12): 1373-8; 2011
59. Wearing-off scales in Parkinson's disease: Critique and recommendations. Antonini A, Martinez-Martin P, Chaudhuri RK, Merello M, Hauser R, Katzenschlager R, Odin P, Stacy M, Stocchi F, Poewe W, Rascol O, Sampaio C, Schrag A, Stebbins GT, Goetz CG. *Mov Disord.* 26 (12): 2169-75; 2011
60. Continuous dopaminergic stimulation and novel formulation of dopamine agonists. Stocchi F. *J Neurol.* 258 (Suppl 2): S316-22; 2011
61. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Rascol O, Fitzner-Attas CJ,



- Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW. *Lancet Neurol.* 10 (5): 415-23; 2011.
62. PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. Stocchi F, Giorgi L, Hunter B, Schapira AH. *Mov Disord.* 26 (7): 1259-65; 2011.
63. Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease. Stocchi F, Zappia M, Dall'Armi V, Kulisevsky J, Lamberti P, Obeso JA; Melevodopa Plus Carbidopa Study Group. *Mov Disord* 15; 25(12): 1881-7; 2010.
64. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW. *Ann Neurol* 68(1): 18-27; 2010.
65. Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. Eggert K, Squillacote D, Barone P, Dodel R, Katzenschlager R, Emre M, Lees AJ, Rascol O, Poewe W, Tolosa E, Trenkwalder C, Onofrij M, Stocchi F, Nappi G, Kostic V, Potic J, Ruzicka E, Oertel W; German Competence Network on Parkinson's Disease. *Mov Disord.* 15;25(7): 896-905; 2010.
66. mGLU3 metabotropic glutamate receptors modulate the differentiation of SVZ-derived neural stem cells towards the astrocytic lineage. Ciceroni C, Mosillo P, Mastrantoni E, Sale P, Ricci-Vitiani L, Biagioni F, Stocchi F, Nicoletti F, Melchiorri D. *Glia.* 58(7): 813-22; 2010
67. The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Chaudhuri KR, Prieto-Jurczynska C, Naidu Y, Mitra T, Frades-Payo B, Tluk S, Ruessmann A, Odin P, Macphee G, Stocchi F, Ondo W, Sethi K, Schapira AH, Martinez Castrillo JC, Martinez-Martin P. *Mov Disord.* 25(6): 697-70; 2010
68. Factors Associated With Motor Fluctuations and Dyskinesia in Parkinson Disease: Potential Role of a New Melevodopa Plus Carbidopa Formulation (Sirio). Stocchi F, Marconi S. *Clin Neuropharmacol.* 33(4):198-203; 2010
69. When Do Levodopa Motor Fluctuations First Appear in Parkinson's Disease? Stocchi F, Jenner P, Obeso JA. *Eur Neurol.* 24;63(5):257-266; 2010
70. The concept of continuous dopaminergic stimulation: what we should consider when starting Parkinson's disease treatment. Stocchi F. *Neurodegener Dis.* 7(1-3):213-5; 2010
71. Clinical Experiences With Levodopa Methylester (Melevodopa) in Patients With Parkinson Disease Experiencing Motor Fluctuations: An Open-Label Observational Study. Zagaglia R, Stocchi F, Sciarretta M, Antonimi A, Mancini F, Guidi M, Martignoni E, Pacchetti C. *Clin Neuropharmacol* 33(2): 66-66; 2010



72. Dopamine receptor agonists in the treatment of advanced Parkinson's disease. Stocchi F. *Parkinsonism Relat Disord.* Dec;15 Suppl 4:S54; 2009
73. The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease. Stocchi F. *Parkinsonism Relat Disord.* Dec;15 Suppl 3:S68-71; 2009
74. Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment. Onofrj M, Bonanni L, Cossu G, Manca D, Stocchi F, Thomas A. *Parkinsonism Relat Disord.* Dec;15 Suppl 3:S233-6; 2009
75. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators. *N Engl J Med* 361(13): 1268-1278; 2009
76. Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. Colosimo C, Morgante L, Antonini A, Barone P, Avarello TP, Bottacchi E, Cannas A, Ceravolo MG, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrone R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Dotto PD, Simoni L, Marconi R; and PRIAMO study group. *J Neurol* 257(1): 5-14; 2010
77. GIGYF2 mutations are not frequent cause of familiar Parkinson's disease. Di Fonzo A, Fabrizio E, Thomas A, Fincati E, Marconi R, Tinazzi M, Breedveld GJ, Simons EJ, Chien HF, Ferreira JJ, Horstink MW, Abbruzzese G, Borroni B, Cossu G, Libera AD, Fabbrini G, Guidi M, De Mari M, Lopiano L, Martignoni E, Marini P, Onofrj M, Padovani A, Stocchi F, Toni V, Sampaio C, Barbosa ER, Meco G, The Italian Parkinson Genetics Network, Oostra BA, Bonifati V. *Parkinsonism Relat Disord.* 15(9): 703-705; 2009
78. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrone R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Dotto PD; on behalf of the PRIAMO study group. *Mov Disord.* 15; 24(11): 1641-1649; 2009
79. Peripheral blood mononuclear cells from mild cognitive impairment patients show deregulation of Bax and Sod1 mRNAs. Gatta L, Cardinale A, Wannenes F, Consoli C, Armani A, Molinari F, Mammi C, Stocchi F, Torti M, Rosano GM, Fini M. *Neurosci Lett.* 27; 453(1): 36-40; 2009
80. Validation of the freezing of gait questionnaire in patients with Parkinson's disease. Giladi N, Tal J, Azulay T, Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe WH, Stocchi F, Tolosa E. *Mov Disord.* 15; 24(5): 655-61; 2009
81. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease. Stocchi F. *Parkinsonism Relat Disord.* 15 Suppl 1: S9-S15; 2009



82. Adherence to antiparkinson medication in a multicenter European study. Grosset D, Antonini A, Canesi M, Pezzoli G, Lees A, Shaw K, Cubo E, Martinez-Martin P, Rascol O, Negre-Pages L, Senard A, Schwarz J, Strecker K, Reichmann H, Storch A, Löhle M, Stocchi F, Grosset K. *Mov Disord.* 30; 24(6): 826-32; 2009
83. Use of Apomorphine in Parkinson's Disease. Stocchi F. *Neurol Sci.* 29 Suppl 5: S383-6; 2009.
84. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, Tolosa E, Stocchi F, Melamed E, Eyal E, Rascol O. *Mov Disord.* 15; 23(15): 2194-201; 2008
85. Treatment of levodopa-induced motor complications. Stocchi F, Tagliati M, Olanow CW. *Mov Disord.* 23 Suppl 3: S599-612; 2008
86. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi LG. *Curr Med Res Opin.* 24(10): 2883-95, 2008
87. Metabotropic glutamate receptors regulate differentiation of embryonic stem cells into GABAergic neurons. Sarichelou I, Cappuccio I, Ferranti F, Mosillo P, Ciceroni C, Sale P, Stocchi F, Battaglia G, Nicoletti F, Melchiorri D. *Cell Death Differ* 15(4): 700-707, 2008
88. Neuroprotection in Parkinson's disease: clinical trials. Stocchi F. *Handb Clin Neurol.* 84: 17-29; 2007
89. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, MacPhee G, Macmahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Naidu Y, Olanow W, Williams AJ, Thomas S, Rye D, Tsuboi Y, Hand A, Schapira AH. *Mov Disord* 22 (13): 1901-1911; 2007
90. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, MacPhee G, Brown RG, Naidu Y, Clayton L, Abe K, Tsuboi Y, MacMahon D, Barone P, Rabey M, Bonuccelli U, Forbes A, Breen K, Tluk S, Olanow CW, Thomas S, Rye D, Hand A, Williams AJ, Ondo W, Chaudhuri KR. *Mov Disord* 22 (11): 1623-1629, 2007
91. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Di Fonzo A, Chien HF, Socal M, Giraudo S, Tassorelli C, Iliceto G, Fabbrini G, Marconi R, Fincati E, Abbruzzese G, Marini P, Squitieri F, Horstink MW, Montagna P, Libera AD, Stocchi F, Goldwurm S, Ferreira JJ, Meco G, Martignoni E, Lopiano L, Jardim LB, Oostra BA, Barbosa ER; The Italian Parkinson Genetics Network; Bonifati V. *Neurology* 68 (19): 1557-1562, 2007



92. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL, EASE-PD Adjunct Study Investigators. *Neurology* 68 (14): 1108-1115; 2007
93. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Stocchi F, Fabbri L, Vecsei L, Krygowska-Wajs A, Monici Preti PA, Ruggieri S. *Clin Neuropharmacol* 30 (1): 18-214; 2007
94. Utility of tolcapone in fluctuating Parkinson's disease. Stocchi F, De Pandis MF. *Clin Interv Aging*.1(4): 317-325; 2006
95. End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease. Thomas A, Bonanni L, Iorio AD, Varanese S, Anzellotti F, D'Andreagiovanni A, Stocchi F, Onofrj M. *J Neurol* 253 (12): 1633-1639; 2006
96. End-of-dose wearing-off in Parkinson's disease: a 9-question survey assessment. Stacy M, Hauser R, Oertel W, Schapira A, Sethi K, Stocchi F, Tolosa E. *Clin Neuropharmacol* 29 (6): 312-321; 2006
97. Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Stocchi F, Vacca L, Grassini P, De Pandis MF, Battaglia G, Cattaneo C, Fariello RG. *Neurology* 67 (suppl 2): S24-29; 2006
98. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease. Olanow CW, Obeso JA, Stocchi F. *Nat Clin Pract Neurol* 2 (7): 382-392, 2006
99. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Olanow CW, Obeso JA, Stocchi F. *Lancet Neurol* 5 (8): 677-687; 2006
100. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarin treatment. Palleschi G, Pastore AL, Stocchi F, Bova G, Inghilleri M, Sigala S, Carbone A. *Clin Neuropharmacol* 29 (4): 220-229; 2006
101. The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations. Stocchi F. *Expert Opin Pharmacother* 7 (10): 1399-1407, 2006
102. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study.. *Mov Disord*. 21 (7): 916-923; 2006
103. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease. Stocchi F. *Int J Clin Pract* 60(2): 215-221; 2006



104. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Di Fonzo A, Tassorelli C, De Mari M, Chien HF, Ferreira J, Rohe CF, Riboldazzi G, Antonini A, Albani G, Mauro A, Marconi R, Abbruzzese G, Lopiano L, Fincati E, Guidi M, Marini P, Stocchi F, Onofrj M, Toni V, Tinazzi M, Fabbrini G, Lamberti P, Vanacore N, Meco G, Leitner P, Uitti RJ, Wszolek ZK, Gasser T, Simons EJ, Breedveld GJ, Goldwurm S, Pezzoli G, Sampaio C, Barbosa E, Martignoni E, Oostra BA, Bonifati V. *Eur J Hum Genet* 14(3): 322-331; 2006
105. The G6055A (G2019S) mutation in LRRK2 is frequent both early and late onset Parkinson's disease and originates from a common ancestor. Goldwurm S, Di Fonzo A, Simons EJ, Rohe CF, Zini M, Canesi M, Tesei S, Zecchinelli A, Antonini A, Mariani C, Meucci N, Sacilotto G, Sironi F, Salani G, Ferreira J, Chien HF, Fabrizio E, Vanacore N, Dalla Libera A, Stocchi F, Diroma C, Lamberti P, Sampaio C, Meco G, Barbosa E, Bertoli-Avella AM, Breedveld GJ, Oostra BA, Pezzoli G, Bonifati V. *J Med Genet* 42(11): e65; 2005
106. Optimising levodopa therapy for the management of Parkinson's disease. Stocchi F. *J Neurol* 252 (supp 4): 43-48; 2005
107. Intermittent vs continuous levodopa administration in patients with advanced Parkinson's disease: a clinical and pharmacokinetic study. Stocchi F, Vacca L, Ruggieri S, Olanow CW. *Arch Neurol* 62 (6): 905-910; 2005
108. Pathological gambling in Parkinson's disease. Stocchi F. *Lancet Neurol* 4 (10): 590-592; 2005
109. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Bonifati V, Rohe CF, Breedveld GJ, Fabrizio E, De Mari M, Tassorelli C, Tavella A, Marconi R, Nicholl DJ, Chien HF, Fincati E, Abbruzzese G, Marini P, De Gaetano A, Horstink MW, Maat-Kievit JA, Sampaio C, Antonini A, Stocchi F, Montagna P, Toni V, Guidi M, Dalla Libera A, Tinazzi M, De Pandis F, Fabbrini G, Goldwurm S, de Klein A, Barbosa E, Lopiano L, Martignoni E, Lamberti P, Vanacore N, Meco G, Oostra BA; Italian Parkinson Genetics Network. *Neurology* 12; 65(1): 87-95; 2005
110. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E; LARGO study group. *Lancet* 12; 365 (9463): 947-54; 2005
111. Identification of motor and nonmotor wearing-off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment. Stacy M, Bowron A, Guttman M, Hauser R, Hughes K, Larsen JP, Lewitt P, Oertel W, Quinn N, Sethi K, Stocchi F. *Mov Disord* 20 (6): 726-33; 2005
112. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Di Fonzo A, Rohe CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E, Manfredi M, Vanacore N, Goldwurm S, Breedveld G, Sampaio C, Meco G, Barbosa E, Oostra BA, Bonifati V; Italian Parkinson Genetics Network. *Lancet* 29; 365(9457):412-415; 2005



113. Novel parkin mutations detected in patients with early-onset Parkinson's disease. Bertoli-Avella AM, Giroud-Benitez JL, Akyol A, Barbosa E, Schaap O, van der Linde HC, Martignoni E, Lopiano L, Lamberti P, Fincati E, Antonini A, Stocchi F, Montagna P, Squitieri F, Marini P, Abbruzzese G, Fabbrini G, Marconi R, Dalla Libera A, Trianni G, Guidi M, De Gaetano A, Boff Maegawa G, De Leo A, Gallai V, de Rosa G, Vanacore N, Meco G, van Duijn CM, Oostra BA, Heutink P, Bonifati V. *Mov Disord*. 2004 Dec 6;
114. Case-control study of multiple system atrophy. Vanacore N, Bonifati V, Fabbrini G, Colosimo C, De Michele G, Marconi R, Stocchi F, Nicholl D, Bonuccelli U, De Mari M, Vieregge P, Meco G. *Mov Disord*. 2004 Sep 20
115. Levodopa in the treatment of Parkinson's disease: current controversies. Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonucelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F. *Mov Disord* 19(9): 997-1005; 2004.
116. Improvement of motor function in early Parkinson disease by safinamide. Stocchi F, Arnold G, Onofrj M, Kwiecinski H, Szczudlik A, Thomas A, Bonuccelli U, Van Dijk A, Cattaneo C, Sala P, Fariello RG; Safinamide Parkinson's Study Group. *Neurology* 63(4): 746-748; 2004.
117. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. Morgante L, Basile G, Epifanio A, Spina E, Antonini A, Stocchi F, Di Rosa E, Martino G, Marconi R, La Spina P, Nicita-Mauro V, Di Rosa AE. *Arch Gerontol Geriatr Suppl*. 9: 291-296; 2004
118. Variation in the Dopaminergic Response During the Day in Parkinson Disease. Monge A, Viselli F, Stocchi F, Barbato L, Bolner A, Modugno N, Paradiso M, Ruggieri S, Nordera G. *Clin Neuropharmacol* 27(3);116-118; 2004
119. Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients. Stocchi F, Barbato L, Nordera G, Bolner A, Caraceni T. *J Neural Transm* 12; 111(2):173-180; 2004
120. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Stocchi F, Olanow CW. *Neurology* 13; 62(1 Suppl 1): S56-63; 2004
121. COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications? Olanow CW, Stocchi F. *Neurology* 13; 62(1 Suppl 1): S72-81; 2004
122. Dual dopamine agonist treatment in Parkinson's disease. Stocchi F, Vacca L, Berardelli A, Onofrj M, Manfredi M, Ruggieri S. *J Neurol* 250: 822-826; 2003



123. Optimizing levodopa pharmacokinetics in Parkinson's disease: the role of COMT inhibitor. Stocchi F, Vacca L, Grassini P, Battaglia G, Onofrj M, Valente M, Ruggieri S. *Neurol Sci* 24: 217-218; 2003
124. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease. Di Rosa AE, Epifanio A, Antonini A, Stocchi F, Martino G, Di Blasi L, Tetto A, Basile G, Imbesi D, La Spina P, Di Raimondo G, Morgante L. *Neurol Sci* 24(3): 174-175; 2003
125. Prevention and treatment of motor fluctuations. Stocchi F. *Parkinsonism Relat Disord* 9 Suppl 2:73-81; 2003
126. Apomorphine infusion and the long-duration response to levodopa in advanced Parkinson's disease. Stocchi F, Berardelli A, Vacca L, Barbato L, Monge A, Nordera G, Ruggieri S. *Clin Neuropharmacol* 26: 151-155; 2003
127. Efficacy and tolerability of Paroxetine for the long-term treatment of generalized anxiety disorder. Stocchi F, Nordera G, Jokinen RH, Lepola UM, Hewett K, Bryson H, Iyengar MK. *J Clin Psychiatry* 64: 250-257; 2003
128. Neuroprotection in Parkinson's Disease: Clinical Trials. Stocchi F, Olanow CW. *Ann Neurol* 53 (suppl 3): S87-S99; 2003
129. Are there clinical significant differences between dopamine agonists. Stocchi F, Vacca L, Onofrj M. *Adv Neurol* 91: 259-266; 2003
130. HLA typing does not predict REM sleep behaviour disorder and hallucinations in Parkinson's disease. Onofrj M, Luciano AL, Iacono D, Thomas A, Stocchi F, Papola F, Adorno D, Di Mascio R. *Mov Disord* 18(3):337-40; 2003
131. Factors impacting on quality of life in Parkinson's disease: Results from an international survey. Stocchi F. with The Global Parkinson's Disease Survey (GPDS) Steering Committee. *Mov Disord* 17: 60-67; 2002
132. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, Stocchi F. *J Neural Transm* 109: 489-501; 2002
133. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Stocchi F, Ruggieri S, Vacca L, Olanow CW. *Brain* 125: 2058-66; 2002
134. Combination of two dopamine agonists in the management of Parkinson's disease. Stocchi F, Berardelli A, Vacca L, Thomas A, De Pandis MF, Modugno N, Valente M, Ruggieri S. *Neurol Sci* 23 (Suppl 2): S115-116; 2002
135. Modification of respiratory function parameters in patients with severe Parkinson's disease. De Pandis MF, Starace A, Stefanelli F, Marruzzo P, Meoli I, De Simone G, Prati R, Stocchi F. *Neurol Sci* 23 (Suppl 2): S69-70; 2002



136. Autosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7. Bonifati V, Dekker MC, Vanacore N, Fabbrini G, Squitieri F, Marconi R, Antonini A, Brustenghi P, Dalla Libera A, De Mari M, Stocchi F, Montagna P, Gallai V, Rizzu P, Van Swieten JC, Oostra B, Van Duijn CM, Meco G, Heutink P. *Neurol Sci* 23 (Suppl 2): S59-60; 2002
137. Managing the critical problems of advanced Parkinson's disease. Stocchi F. *Expert Rev Neurotherapeutics* 2: 835-847; 2002
138. Long-duration effect and the postsynaptic compartment: Study using a dopamine agonist with a short half-life. Stocchi F, Vacca L, Berardelli A, DePandis MF, Ruggieri S. *Mov Disord* 16: 301-305; 2001.
139. Sleep disorders in Parkinson's disease. Stocchi F, Vacca L, Valente M, Ruggieri S. *Adv Neurol* 86 (29): 289-293; 2001.
140. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S. *Neurol Sci* 22: 93-4; 2001
141. Epidemiology of multiple system atrophy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. Vanacore N, Bonifati V, Fabbrini G, Colosimo C, De Michele G, Marconi R, Nicholl D, Locuratolo N, Talarico G, Romano S, Stocchi F, Bonuccelli U, De Mari M, Vieregge P, Meco G. *Neurol Sci* 22: 97-9; 2001
142. Epidemiology of progressive supranuclear palsy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. Vanacore N, Bonifati V, Colosimo C, Fabbrini G, De Michele G, Marconi R, Nicholl D, Locuratolo N, Romano S, Talarico G, Stocchi F, Bonuccelli U, Lamberti P, Vieregge P, Meco G. *Neurol Sci* 22: 101-103; 2001
143. Anorectal function in multiple system atrophy and Parkinson's disease. Stocchi F, Badiali D, Vacca L, D'Alba L, Bracci F, Ruggieri S, Torti M, Berardelli A, Corazziari E. *Mov Disord* 15(1):71-6; 2000.
144. Smoking habits in multiple system atrophy and progressive supranuclear palsy. Vanacore N, Bonifati V, Fabbrini G, Colosimo C, Marconi R, Nicholl DJ, Bonuccelli U, Stocchi F, Lamberti P, Volpe G, De Michele G, Iavarone I, Bennett P, Vieregge P, Meco G and the European Study Group of Atypical Parkinsonism. *Neurology* 54: 114-119; 2000.
145. Cognition and emotion in different stages and subtypes of Parkinson's disease. Stocchi F, Brusa L. *J Neurol* 247: II 114- II 121; 2000.
146. Why delaying levodopa is a good treatment strategy in early Parkinson's disease. Olanow CW, Stocchi F. *Eur J Neurol* 7 (suppl. 1): 3-7; 2000.
147. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Nutt JG, Obeso JO, Stocchi F. *Trends Neurosci* 23 (suppl.): S109-S115; 2000.



148. Sympatetic skin response and carddiovascolar autonomic function tests in Parkinson's disease and multiple system atrophy with autonomic failure. De Marinis M, Stocchi F, Gregori B, Accornero N. *Mov Disord* 15: 1215-1220; 2000.
149. Sleep disturbances in Parkinson's Disease. Stocchi F, Brusa L, Vacca L, De Pandis MF, Grassini P, Berardelli A, Ruggieri S. *Eur J Neurol* 7 (suppl. 4): 21-25; 2000.
150. Dopamine agonists in Parkinson's disease: What is their role in early treatment? Stocchi F. In: *Drug Treatment Issues in Parkinson's Disease*. KJ Palmer Ed. Adis International. pp 27-40; 2000.
151. Implantable venous access system for apomorphine infusion in complicated Parkinson's disease. Stocchi F, Farina C, Nordera GP, Ruggieri S. *Mov Disord* 14 (2): 358; 1999.
152. The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease. Taylor A, Beerah A, Citerone D, Davy M, Fitzpatrick K, Lopez-Gil A, Stocchi F. *Br J Clin Pharmacol* 47 (2): 219-222; 1999.
153. Urinary and anorectal function in Parkinson's disease. Stocchi F, Corazziari E, Carbone A, Vacca L, DePandis MF, Berardelli A, Ruggieri S. *Adv Neurol* 80 (45): 347-351; 1999.
154. Disorders of bowel function in Parkinsonism. Stocchi F. In: *Blue Books of Pratical Neurology: Neurology of bladder, bowel, and sexual dysfunction*. Ed. CJ Fowler. Vol. 23 (16): 255-264; 1999.
155. Increased expression of dopamine receptors on lymphocytes in Parkinson's disease. Barbanti P, Fabbrini G, Ricci A, Cerbo R, Bronzetti E, Caronti B, Calderaro C, Felici L, Stocchi F, Meco G, Amenta F, Lenzi GL. *Mov Disord* 14 (5): 764-771; 1999.
156. A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. Nicholl DJ, Bennett P, Hiller L, Bonifati V, Vanacore N, Fabbrini G, Marconi R, Colosimo C, Lamberti P, Stocchi F, Bonuccelli U, Vieregge P, Ramsden DB, Meco G, Williams AC for the European Study Group of Atypical Parkinsonism. *Neurology* 53: 1415-21; 1999
157. The tau gene in progressive supranuclear palsy: exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases. Bonifati V, Joosse M, Nicholl DJ, Vanacore N, Bennett P, Rizzu P, Fabbrini G, Marconi R, Colosimo C, Locuratolo N, Stocchi F, Bonuccelli U, De Mari M, Wenning G, Vieregge P, Oostra G, Meco G, Heutink P. *Neurosci Lett* 274 (1): 61-5; 1999
158. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Agid Y, Ahlskog Y, Albanese A, Calne D, Chase T, De Yebenes J, Factor S, Fahn S, Gershanik O, Goetz C, Koller W, Kurth M, Lang A, Lees A, Lewitt P, Marsden D, Melamed E, Michel PP, Mizuno Y, Obeso J, Oertel W, Olanow W, Poewe W, Pollak



- P, Przedzorski S, Quinn N, Raisman-Vozari R, Rajput A, Stocchi F, Tolosa E. *Mov Disord* 14: 911-913; 1999.
159. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. Rascol O, Brooks JD, Brunt ER, Korczyn AD, Poewe WH, Stocchi F. *Mov Disord* 13 (1): 39-45; 1998.
160. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. Korczyn AD, Brooks JD, Brunt ER, Poewe WH, Rascol O, Stocchi F. *Mov Disord* 13 (1): 46-51; 1998.
161. Continuous dopaminergic stimulation in Parkinson's disease treatment. Stocchi F. *Focus on Parkinson's Disease* 10: 60-63; 1998
162. An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines. (Stocchi F. and other authors) *Neurology* 50 (suppl.3): 1-57; 1998
163. Sleep disorders in Parkinson's disease. Stocchi F, Barbato L, Nordera G, Berardelli A, Ruggieri A. *J Neurol* 245 (suppl.3): S15-S18; 1998.
164. The safety of Ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. Schrag AE, Brooks DJ, Brunt E, Fuell D, Korczyn A, Poewe W, Queen NP, Rascol O, Stocchi F. *Clin Neuropharmacol* 21 (3):169-175; 1998.
165. Dopamine agonists in Parkinson's disease: What is their role in early treatment? Stocchi F. *CNS Drugs* 10 (3): 159-170; 1998.
166. Direct genetic evidence for involvement of TAU in progressive supranuclear palsy. Bennet P, Bonifati V, Bonuccelli U, Colosimo C, DeMari M, Fabbrini G, Marconi R, Meo G, Nicholl DJ, Stocchi F, Vanacore N, Vieregge P, Williams AC for the European Study Group of Atypical Parkinsonism. *Neurology* 51: 982-985; 1998.
167. Co-administration of ropinirole and domperidone during rapid dose escalation of the dopamine agonist. Stocchi F, Destée A. *Parkinsonism and Related Disorders* 4: 183-188; 1998.
168. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Stocchi F, Nordera GP, Marsden CD. *Clin Neuropharmacol* 20 (2): 95-115; 1997
169. Urodynamic and neurophysiological evaluation in Parkinson's disease and Multiple System Atrophy. Stocchi F, Carbone A, Inghilleri M, Monge A, Ruggieri S, Berardelli A, Manfredi M. *J Neurol Neurosurg Psychiatry* 62 (5): 507-511; 1997
170. The influence of age on the use of dopamine agonists as primary symptomatic therapy. Stocchi F. In: *Beyond the decade of the brain*. Vol. 2 Ed. W. Olanow, JA. Obeso: 187-193; 1997



171. Low dose of Clozapine in the treatment of dopaminergic psychosis in Parkinson's disease. Ruggieri S, De Pandis MF, Bonamartini A, Vacca L, Stocchi F. *Clin Neuropharmacol* 20 (3): 204-209; 1997.
172. The long-duration action of levodopa may be due to a postsynaptic effect. Barbato L, Stocchi F, Monge A, Vacca L, Ruggieri S, Nordera GP, Marsden CD. *Clin Neuropharmacol* 20 (5):394-401; 1997.
173. An acute a long-term study with a dispersible formulation of levodopa-benserazide (Madopar) in Parkinson's disease. Monge A, Barbato L, Stocchi F, Nordera GP. *Eur J Neurology* 4: 485-490; 1997.
174. Determination of apomorphine in human plasma by alumina extraction and high-performance liquid chromatography with electrochemical detection. Bolner A, Barbato L, Tagliaro F, Monge A, Stocchi F, Nordera GP. *Forensic Science International* 89: 81-91; 1997.
175. Management of gastrointestinal alterations in Parkinson's disease. Stocchi F. In: *NeUroGastroenterology*. E. Corazziari Eds. 235-241; 1996
176. QT interval and QT dispersion in multiple system atrophy. Frongillo D, Stocchi F, Delfino FA, Calò L, Bramante L, Antonucci F, De Nardo D, Ruggieri S, Cannata D. *Clin Auton Research* 6: 67-70; 1996.
177. Motor fluctuations in Levodopa treatment: clinical pharmacology. Stocchi F, Bonamartini A, Vacca L, Ruggieri S. *Eur Neurol* 36 (suppl.1): 38-42; 1996.
178. Fluctuating parkinsonism: a pilot study of a single afternoon dose of levodopa methyl ester. Stocchi F, Barbato L, Bramante L, Nordera G, Vacca L, Ruggieri S. *J Neurol* 243: 377-380; 1996.
179. An open study with reversible MAO-A inhibitors in complicated Parkinson's disease. Ruggieri S, Fabbrini G, Bramante L, De Pandis F, Stocchi F, Barbanti P, Vacca L, Manfredi M. *Adv Neurol* 69: 595-598; 1996.
180. Instrumental diagnosis of multiple system atrophy. Stocchi F, Carbone A, Inghilleri M, Frongillo D, Barbato L, Bramante L, Cannata D, Manfredi M, Ruggieri S. *Adv Neurol* 69: 421-424; 1996.
181. A pharmacological study of cocaine activity in Planaria. Palladini G, Ruggieri S, Stocchi F, De Pandis MF, Venturini G, Margotta V. *Comp Biochem Physiol* 115c: 41-45; 1996.
182. Transient Atrial fibrillation after subcutaneous Apomorphine bolus. Stocchi F, De Pandis MF, Delfino F, Anselmo T, Frongillo D. *Mov Disord* 11: 584-585; 1996.
183. Melperone in the treatment of iatrogenic psychosis in Parkinson's disease. Barbato L, Monge A, Stocchi F, Nordera GP. *Funct Neurol* 11 (4): 201-207; 1996.



184. The Bereitschaftspotential preceding stepping in patients with isolated gait ignition failure. Vidailhet M, Atchison PR, Stocchi F, Thompson PH, Rothwell JC, Marsden CD. *Mov Disord* 10 (1):18-21; 1995.
185. Differential diagnosis of parkinsonism. Manfredi M, Stocchi F, Vacca L. *J Neural Transm* 45 (suppl.): 1-9; 1995.
186. Ambulatory blood pressure monitoring and cardiovascular function tests in Multiple system atrophy. Frongillo D, Stocchi F, Buccolini P, Stecconi P, Viselli F, Ruggieri S, Cannata. *Clin Fundam Pharmacol* 9: 187-196; 1995.
187. An algorithm for the management of Parkinson's disease. (Stocchi F. and other authors) *Neurology* 44 (suppl.10): 1-52; 1994
188. Analysis of repetitive and nonrepetitive sequential arm movements in patients with Parkinson's disease. Agostino R, Berardelli A, Formica A, Stocchi F, Accornero N, Manfredi M. *Mov Disord* 9 (3): 311-314; 1994
189. Comparison between a fast and slow release preparation of levodopa and combination of the two: a clinical and pharmacokinetic study. Stocchi F, Quinn NP, Barbato L, Patsalos P, O'Connell MT, Ruggieri S, Marsden CD. *Clin Neuropharmacol* 17 (1): 38-44; 1994.
190. Symptomatic improvement without clinical fluctuations: success markers and future success objectives. Stocchi F. In: *Beyond the decade of the brain*. Eds. MB Stern. Chapter three; 47-55; 1994
191. Clinical implications of sustained dopaminergic stimulation. Stocchi F, Patsalos PN, Berardelli A, Barbato L, Bonamartini A, Manfredi M, Ruggieri S. *Clin Neuropharmacol* 17 (2): S7-S13; 1994
192. The clinical efficacy of a single dose afternoon dose of levodopa methyl ester: a double-blind cross-over study versus placebo. Stocchi F, Barbato L, Bramante L, Bonamartini A, Ruggieri S. *Funct Neurol* 9: 259-264; 1994
193. Clinical efficacy of single morning doses of different levodopa formulations. Stocchi F, Ruggieri S, Monge A, Nordera G, Bolner P, Viselli F, Bramante L, Quinn NP, De Pandis MF, Manfredi M. *Clin Neuropharmacol* 17 (suppl. 3): S16-S20; 1994
194. Emergencies in Parkinson's disease. Stocchi F, Ruggieri S. In: *New advances in Parkinson's disease and other extrapyramidal diseases; Update on Parkinson's disease*. Nappi, Caraceni, Martgnoni Eds. Cap. 12: 95-98; 1994
195. Apomorphine and Lisuride infusion: A Comparative Study. Stocchi F, Bramante L, Monge A, Viselli F, Baronti F, Stefano E, Ruggieri S. *Adv Neurol* 60; 653-655; 1993
196. Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group. Berardelli A, Formica A, Mercuri B, Abbruzzese G, Agnoli A, Agostino R, Caraceni T, Carella F, DeFazio F, DeGrandis D, Elopea R, Girlanda P, Lepore V, Messina C, Milone S, Priori A, Stocchi F, Tugnoli V, Manfredi. *Ital J Neurol Sci* 14: 361-367; 1993



197. Urodynamic Study in the Differential Diagnosis Between Multiple System Atrophy and Parkinson's Disease. Stocchi F, Barbato L, Carbone A, Fabbrini G, Ruggieri S, Bonamartini A, Baffigo G, Agnoli A. *Adv Neurol* 60; 434-437; 1993
198. The Bereitschaftspotentials preceding simple foot movement and initiation of gait in Parkinson's Disease. Vidailhet M, Stocchi F, Rothwell JC, Thompson PD, Day BL, Brooks DJ, Marsden CD. *Neurology* 43: 1784-1788; 1993
199. Transient left bundle branch block following intravenous lisuride bolus. Capria A, Attanasio A, Frongillo D, Ruggieri S, Stocchi F. *Fundam Clin Pharmacol* 7:115-117; 1993.
200. Pulsatile versus continuous dopaminergic stimulation. Stocchi F, Barbato L, Viselli F, DePandis MF, Ruggieri S. In: 20 years of Madopar New avenues. W Poewe and A Lees Eds. Basel 129-135; 1993
201. TRH Test and the Continuous Dopaminergic Stimulation in Complicated Parkinson's Disease. Lestingi L, Bonifati V, Stocchi F, Antonozzi I, Meco G. *Eur Neurol* 32: 65-69; 1992
202. HPLC monitoring of plasma catechol levels in the characterization of Parkinson's disease. Betto P, Ricciarello G, Ruggieri S, Stocchi F, Baronti F, Nappi G, Martignoni E, Melzi D'Eril, Blandini F, Lucarelli C. *Giorn It Chim Clin* 17 (6): 441-453; 1992
203. Intravenous Boluses and Continuous Infusions of L-Dopa Methyl Ester in Fluctuating Patients with Parkinson's Disease. Stocchi F, Ruggieri S, Carta A, Ryatt J, Quinn NP, Jenner P, Marsden CD, Agnoli A. *Mov Disord* 7 (3): 249-256; 1992
204. The clinical efficacy of single morning doses of levodopa methyl ester, Dispersible Madopar and Sinemet plus in Parkinson's disease. Steiger MJ, Stocchi F, Bramante L, Ruggieri S, Quinn NP. *Clin Neuropharmacol* 15 (6): 501-504; 1992
205. Subcutaneous Lisuride Infusion. Stocchi F, Ruggieri S, Viselli F, Bramante L, Monge A, Barbato L, Agnoli A. In: *New trends in clinical Neurology: Parenteral drug therapy in spasticity and Parkinson's disease*; J.P.W.F. Lakke, E.M. Delhaas, A.W.F. Rutgers Eds. The Parthenon Publishing group USA; 205-211; 1992.
206. Intrajejunal infusion of L-Dopa methylester. Stocchi F, Ruggieri S, Bramante L, De Pandis MF, Lucarelli C, Agnoli A. In: *Parkinson's disease and extrapyramidal disorders, pathophysiology and treatment*. A. Agnoli, G. Fabbrini, F. Stocchi, Eds. John Libbey; 287-290; 1991
207. Long term treatment with subcutaneous Lisuride infusion in Parkinson's disease: cardiovascular effects. Capria A, Attanasio A, Piccolo CG, Fabrizio E, Innocenti F, Stocchi F, Ruggieri S. In: *Parkinson's disease and extrapyramidal disorders, pathophysiology and treatment*; A. Agnoli, G. Fabbrini, F. Stocchi, Eds. John Libbey; 373-375; 1991



208. Cardiovascular effects of repeated intravenous Lisuride infusions. Attanasio A, Capria A, Leggiadro G, Michisanti M, Marchetti M, Frongillo D, Stocchi F, Ruggieri S. In: Parkinson's disease and extrapyramidal disorders, pathophysiology and treatment; A. Agnoli, G. Fabbrini, F. Stocchi, Eds. John Libbey; 377-380; 1991
209. A pharmacological study of dopaminergic receptors in planaria. Palladini G, Stocchi F, Margotta V, Ruggieri S, Bocciarelli P, Bonamartini A, De Pandis F, Venturini G. In: Parkinson's disease and extrapyramidal disorders, pathophysiology and treatment. A. Agnoli, G. Fabbrini, F. Stocchi, Eds. John Libbey; 389-393; 1991
210. Urodynamic study in Parkinsonism and MSA. Carbone A, Stocchi F, Viselli F, Baffigo G, Bocciarelli P, Bonamartini A, Agnoli A. In: Parkinson's disease and extrapyramidal disorders, pathophysiology and treatment, A. Agnoli, G. Fabbrini, F. Stocchi. Eds. John Libbey; 471-473; 1991
211. Sweating alterations in Parkinson's disease De Marinis M, Stocchi F, Testa SR, De Pandis MF, Agnoli A. In: Parkinson's disease and extrapyramidal disorders, pathophysiology and treatment, A. Agnoli, G. Fabbrini, F. Stocchi. Eds. John Libbey; 489-493; 1991
212. A Multicentre trial with Madopar HBS in fluctuatory parkinsonian patients. Stocchi F, Giorgi L, Bravi D, Ruggieri S, Monge A, Bramante L, Agnoli A. In: New Developments in Therapy of Parkinson's Disease. A. Agnoli, G. Campanella, Eds. John Libbey CIC s.r.l.; 1991
213. The clinical efficacy of oral Levodopa Methyl Ester solution in reversing afternoon "off" periods in Parkinson's disease. Steiger MJ, Stocchi F, Carta A, Ruggieri S, Agnoli A, Quinn NP, Marsden CD. Clin Neuropharmacol 14 (3):241-244; 1991
214. Antagonist effect of Tergurite in Parkinson's disease. Ruggieri S, Stocchi F, Baronti F, Viselli F, Horowski R, Lucarelli C, Agnoli A. Clin Neuropharmacol 14 (5): 450; 1991
215. Alterations of thermoregulation in Parkinson's disease. De Marinis M, Stocchi F, Testa SR, De Pandis MF, Agnoli A. Functional Neurol 6 (3):279-283; 1991
216. Subcutaneous continuous infusion in fluctuating patients with Parkinson's disease: apomorphine and Lisuride. Stocchi F, Ruggieri S, Bramante L, Monge A, Viselli F, Lucarelli C, Agnoli A. In: International Workshop Berlin Parkinson's disease. How to proceed today in treatment from basic research and Early diagnosis to long-treatment. U.K. Rinne, T. Nagatsu, R. Horowski Eds. 296-306; 1991
217. Botulinum A toxin in patients with blepharospasm, torticollis and hemifacial spasm. Berardelli A, Carta A, Stocchi F, Formica A, Agnoli A, Manfredi M. Ital J Neurol Sci 11: 589-593, 1990
218. Simultaneous measurement of L-Dopa, its metabolites and carbidopa in plasma of Parkinsonian patients by improved sample pretreatment and high-performance liquid chromatographic determination. Lucarelli C, Betto P, Ricciarello G, Giambenedetti M, Corradini C, Stocchi F, Beliaro F. J Chromatography 511: 167-176; 1990



219. D1 and D2 receptors in planaria. Palladini G, Stocchi F, Bravi D, Giorgi L, Margotta V, Venturini G. 89-94, 1990
220. Levodopa and Lisuride intravenous infusion in fluctuating Parkinsonian patients: clinical differences. Stocchi F, Carta A, Ruggieri S, Barbato L, Buonopane A, Bramante L, Viselli F, Agnoli A. In: Motor Disturbances II. A. Berardelli, R. Bencke, M. Manfredi, and C. D. Marsden Eds. 151-160; 1990
221. Differential diagnosis of Parkinson's disease. Agnoli A, Stocchi F, Carta A. In: Early Markers in Parkinson's disease and Alzheimer's disease. (New vistas in drug research, Vol.1) Eds by Springer-Verlag; 13-21; 1990
222. Current status of pharmacologic therapy in complicated Parkinson's disease. Carta A, Stocchi F, Ruggieri S, Agnoli A. *Funct Neurol (Suppl.1)*; 1990
223. Transient cardiac arrest during continuous intravenous infusion of apomorphine. Attanasio A, Capria A, Leggiadro G, Michisanti M, Cannata D, Stocchi F, Ruggieri S. *The Lancet* ii: 1321; 1990
224. Bromocriptine SRO in Parkinson's disease: preliminary results. Stocchi F, DePandis MF, Fabbrini G, Ruggieri S, Bocciarelli S, Agnoli A. *New Trends Clin Neuropharm* 4 (2): 35-40; 1990
225. Cardiovascular effects of lisuride continuous intravenous infusion in fluctuating Parkinson's disease. Capria A, Attanasio A, Quatrana M, Cannata D, Fioravanti M, Stocchi F, Ruggieri S. *Clin Neuropharmacol* 12 (4): 331-338; 1989
226. Side effects of subcutaneous apomorphine in Parkinson's disease. Ruggieri S, Stocchi F, Carta A, Agnoli A. *The Lancet* i: 566; 1989
227. One year treatment with lisuride delivery pump in Parkinson's disease. Ruggieri S, Stocchi F, Carta A, Bragoni M, Agostini C, Barbato L, Agnoli A. *Prog Neuro-Psychopharmacol Biol Psychiat* 13: 173-183; 1989
228. An overview of new therapeutic strategies in Parkinson's disease. Carta A, Stocchi F, Brughitta G, Antonini A, Ruggieri S, Agnoli A. *Funct Neurol* 4 (4): 53-57; 1989
229. Different therapeutic approaches to complicated Parkinson disease. Stocchi F, Ruggieri S, Carta A, Jenner P, Agnoli A. In: Disorders of Movement. NP Quinn and PG Jenner Eds. Academy Press London; 137-146; 1989
230. Latest therapeutic strategies in complicated Parkinson's disease. Agnoli A, Carta A, Stocchi F, Brughitta G, Giorgi L, Ruggieri S. In: Parkinsonism and aging, Donald B. Calne et. Al., Eds. Raven Press, Ltd., New York; 287-292; 1989
231. Jejunal delivery of L-Dopa Methyl Ester. Ruggieri S, Stocchi F, Carta A, Cartarci M, Agnoli A. *The Lancet* ii: 45; 1989
232. Oral sustained-release preparation of L-Dopa in the management of fluctuations in Parkinson's disease: 6 months follow-up. Stocchi F, Bragoni M, Monge A, Bravi D,



- Giorgi L, Viselli F, Ruggieri S. *New Trends Clin Neuropharmacol* 3 (1): 29-38; 1989
233. A Pharmacological study of dopaminergic receptors in planaria. Venturini G, Stocchi F, Margotta V, Ruggieri S, Bravi D, Bellantuono P, Palladini G. *Neuropharmacology* 28 (12): 543-55; 1989
234. Effects of terguride in patients with Huntington's disease. Stocchi F, Carta A, Berardelli A, Antonini A, Argenta M, Formica A, Agnoli A. *Clin Neuropharmacol* 12 (5):435-439; 1989
235. Terguride versus placebo: a double blind cross-over study in patients with Huntington's disease. Stocchi F, Carta A, Ruggieri S, Berardelli A, Buonopane A, Monge A, Agnoli A. In: *Neurology in Europe*. D. Bartko, F. Gesternbrand, P. Turconi, Eds. John Libbey London; 578-581; 1989
236. Continuous dopaminergic stimulation in the management of complicated Parkinson's Disease. Agnoli A, Stocchi F, Carta A, Antonini A, Bragoni M, Ruggieri S. *The Mount Sinai Journal of Medicine* 55 (1): 62-66; 1988
237. Subcutaneous Lisuride infusion in Parkinson's disease: clinical results using different modes of administration. Stocchi F, Ruggieri S, Antonini A, Baronti F, Brughitta G, Bellantuono P, Bravi D, Agnoli A. *J Neural Transm (Suppl)* 27: 27-33; 1988
238. Pharmacokinetics of Lisuride after subcutaneous infusion. Krause W, Nieuweboer B, Ruggieri S, Stocchi F, Suchy I. *J Neural Transm (Suppl)* 27: 71-74; 1988
239. Parkinson's disease and continuous infusion of dopaminergic agonists: The role of α -dihydroergocryptine. Stocchi F, Ruggieri S, Bragoni M, Giorgi L, Bravi D, Carta A, Agnoli A. *New Trends Clin Neuropharmacol* D. Bartko et al. Eds John Libbey Ltd London; 262-267; 1988
240. Comprehensive clinical approach to parkinsonism with dementia: neurological and neuropsychological study. Stocchi F, Carta A, Ruggieri S, Feliciani M, Fioravanti M, Gallucci M, Monge A, Rossi F, Agnoli A. In: *Senile dementias. II International symposium* Eds. A. Agnoli, J. Cohn, N. Lassen, R. Mayeux. John Libbey Eurotel; 261-264; 1988
241. Dopamine agonists in the treatment of Parkinson's disease: comparison between dihydroergocryptine and bromocriptine. Ruggieri S, Stocchi F, Carta A, Bravi D, Giorgi L, Bragoni M, Agnoli A. *New Trends Clin Neuropharmacol* 2 (1): 63-69; 1988
242. Comparison between oral L-dopa and oral L-Dopa methyl ester in fluctuating Parkinson's Disease. Ruggieri S, Stocchi F, Carta A, Jenner P, Coleman RJ, Marsden CD, Agnoli A. *New Trends Clinical Neuropharmacol* D. Bartko et al. Eds.; John Libbey Ltd London; 268-272; 1988
243. Madopar hydrodynamically balanced system in the management of Parkinson's disease. Carta A, Stocchi F, Ruggieri S, Baronti F, Bravi D, Agnoli A. *New Trends*



- Clinical Neuropharmacol D. Batko et al. Eds.; John Libbey Ltd London; 257-261; 1988
244. Comparison between L-Dopa and Lisuride intravenous infusion: a clinical study. Ruggieri S, Stocchi F, Carta A, Bravi D, Bragoni M, Giorgi L, Agnoli A. *Mov Disord* 3 (4): 313-319; 1988
245. Pharmacological strategies for controlling motor fluctuations in Parkinson's disease. Ruggieri S, Carta A, Stocchi F, Antonini N, Bellantuono P, Monge A. *Funct Neurology* 3 (4): 471-479; 1988
246. Improved High-Performances liquid chromatographic analysis with double detection system for L-Dopa, its metabolites and Carbidopa in plasma of Parkinsonian patients under L-Dopa therapy. Betto P, Ricciarello G, Gianbenedetti M, Lucarelli C, Ruggieri S, Stocchi F. *J Chromatography* 459: 349-349; 1988
247. Correlation between facial involuntary movements and abnormalities of blink and corneal reflexes in Huntington's chorea. Agostino R, Berardelli A, Cruccu G, Paoletti G, Stocchi F, Manfredi M. *Mov Disord* 3 (4): 281-289; 1988
248. New strategies in the treatment of Parkinson's disease Stocchi F, Ruggieri S, Carta A, Quinn NP, Jenner P, Coleman RJ, Bragoni M, Marsden CD, Agnoli A. In: *Progress in catecholamin research*. RH Belmaker, M. Sandler, A. Dahlstrom Eds, Alan R. Liss N.Y; Vol 42c: 13-17; 1988
249. Lisuride infusion in chronically treated fluctuating Parkinson's Disease: effects of continuous dopaminergic stimulation. Ruggieri S, Stocchi F, Bellantuono P, Antonini A, Carta A, Agnoli A. *New Trends Clin Neuropharmacol* 1 (1): 55-60; 1987
250. Single-Dose studies of a Slow-Release Preparation of Levodopa and Benzerazide (Madopar HBS) in Parkinson's disease. Marion MH, Stocchi F, Malcom SL, Quinn NP, Jenner P, Marsden CD. *Eur Neurol* 27 (suppl.1): 54-58; 1987
251. Neurophysiological and magnetic resonances studies in a patient with hemiballismus. Berardelli A, Stocchi F, Gallucci M, Ruggieri S, Accornero N, Agnoli A, Manfredi M. *Funct Neurology* 2 (2): 93-98; 1987
252. Unusual Cardiovascular Response to Intravenous Lisuride Bolus. Capria A, Stocchi F, Attanasio A, Quatrana M, Cannata D, Ruggieri S. *Chest* 91: 792-793; 1987
253. Corneal and blink reflexes in Parkinson's Disease with on-off fluctuations. Agostino R, Berardelli A, Cruccu G, Stocchi F, Manfredi M. *Mov Disord* 2: 87-103; 1987
254. Tardive Dyskinesias: An up to date restatement. Ruggieri S, Stocchi F, Carta A, Bellantuono P, Bravi D, Agnoli A. In: *International Symposium on Neurotoxicology*. Turin 5-7/7/87 CIC eds., 42-45, 1987



255. High-Performance liquid chromatography with coulometric detection of plasma Carbidopa, L-Dopa and its metabolites in Parkinsonian patients. Lucarelli C, Betto P, Gianbenedetti M, Ricciarello G, Ruggieri S, Stocchi F. *Giorn It Chim Clin* 12 (3): 223-229; 1987
256. The role of MAO-B inhibitors in the treatment of Parkinson's disease. Ruggieri S, Stocchi F, Denaro A, Baronti F, Agnoli A. *J Neural Trans (suppl. 22)*: 227-233; 1986
257. Multicenter Trial of L-Deprenyl in Parkinson's Disease. Ruggieri S, Denaro A, Meco G, Carta A, Stocchi F, Agnoli A. *Ital J Neurol Sciences* 7: 133-137; 1986
258. Repeated L-Dopa infusions in fluctuating Parkinson's Disease: clinical and pharmacokinetic data. Marion MH, Stocchi F, Quinn NP, Jenner P, Marsden CD. *Clin Neuropharmacol* 9 (2): 165-181; 1986
259. Single dose study of slow release preparation of levodopa and Benserazide (Madopar HBS) in Parkinson's Disease. Marion MH, Stocchi F, Quinn NP, Jenner P, Marsden CD. *Adv Neurol* 45: 493-496 1986
260. Problems in daily motor performances in Parkinson's Disease: The continuous dopaminergic stimulation. Stocchi F, Ruggieri S, Brughitta G, Agnoli A. *J Neural Transm (suppl. 22)*: 209-218; 1986
261. Lisuride infusion Pump for Parkinson's Disease. Ruggieri S, Stocchi F, Agnoli A. *The Lancet*, ii: 348-349; 1986
262. Intravenous dopamine agonist studies in Parkinson's Disease. Quinn NP, Marion MH, Stocchi F, Jenner P, Marsden CD. In: *Recent developments in Parkinson's Disease*. S. Fahn et al. Eds. Raven Press, New York, 247-253; 1986
263. White matter disease (Binswanger's Encephalopathy) in chronic cerebrovascular disorders. Agnoli A, Ruggieri S, Denaro A, Martucci N, Tafani G, Stocchi F. *Monogr Neural Sci Eds Karger-Basel*. Vol. 11: 144-149; 1984
264. Management of L-Dopa induced abnormal involuntary movements in Parkinson disease. Agnoli A, Ruggieri S, Meco G, Denaro A, Stocchi F. *Neuropsychiatr Clin* 3: 203-205; 1984
265. Thyrotropin releasing hormone in neurological disease. Agnoli A, Ruggieri S, Denaro A, Stocchi F, Baldassarre N, Meco G. *Clin Neuropharmacol* 7 (suppl.1): 736-737; 1984
266. Clinical efficacy of Budipine in the treatment of Parkinson's disease: Anticholinergic of dopaminergic effect. Ruggieri S, Agnoli A, Denaro A, Stocchi F, Meco G, Baldassarre M, Cusimano G. *Clin Neuropharmacol* 7 (suppl.1): 952-953; 1984
267. An appraisal of the problem of dementia in Parkinson's disease. Agnoli A, Ruggieri S, Meco G, Casacchia M, Denaro A, Conti L, Bedini L, Stocchi F, Fioravanti F, Franzese A, Lazzari R. *Adv Neurol* 40: 299-306; 1984



268. On the relationship between parkinsonism and dementia. Ruggieri S, Conti L, Stocchi F, Baldassarre M, Denaro A, Agnoli A. In: Aging of the brain. D. Samuel et al. Eds. Raven Press, New York; 33-45; 1983
269. Current Concept in the treatment of Parkinson's disease: use of citicoline. Agnoli A, Ruggieri S, Baldassarre M, Stocchi F, Dal Roscio S, Gallucci M, Scapagnini U. In: Current concept of parkinson disease and related disorders. M. D. Yahr Eds, Excerpta Medica Amsterdam; 124-144; 1983
270. Dopaminergic ergots in Parkinsonism. Agnoli A, Ruggieri S, Baldassarre M, Stocchi F, Denaro A, Falaschi P. In: Lisuride and other dopamine agonists, D. B. Calne et al. Eds. Raven Press, New York; 407-417; 1983
271. Neuroendocrin rhythm in depression. Baldassarre M, Falaschi P, Ruggieri S, Stocchi F, Rocco A, Agnoli A. In: Neuropeptide and psychosomatic processes. Akademiai Kiado Budapest. Eds. Endroczi et al; 625-635; 1982
272. Comparison between therapeutic activity of lisuride and bromocriptine in Parkinson's disease. Agnoli A, Ruggieri S, Baldassarre M, De Roscio S, Stocchi F, Martucci N. Pharmacology 24: 134-135; 1982
273. Today's Therapy and Need for Futur Therapy of Chronic Cerebral Vascular Diseases. Agnoli A, Baldassarre M, Stocchi F, Del Roscio S, Gallucci M, Ruggieri S. In: Proc Int Drug Studies in CVD and PVD. Pergamon Press; 77-82; 1981

Book Chapter

Co-editing, "Wiley-Blackwell", A John Wiley & Son, Ltd, Publication:

Parkinson's Disease: non-motor and non-dopaminergic features. Edited by: CW Olanow, F Stocchi, AE Lang. 2011

- Chapter 25: Blader dysfunction in Parkinson's disease and other parkinsonism. Stocchi F, Torti M, Palleschi G, Carbone A. 274-283

Principles of Treatment in Parkinson's Disease. Edited by: Schapira, A., Olanow, C.W. Elsevier Inc. 2005

- **Chapter: Gastrointestinal, urological, and sleep problems in parkinson's disease.** Stocchi F. 251-275

Parkinsonian Disorders in Clinical Practice. Edited by: Schapira, A., Hartmann, A., Agid, Y., John Wiley and Sons. 2009

- Chapter: Case Study 10. Stocchi F. 107-111

